65,437 trials
Covid19 · Intellectual Disability · Developmental Disability
Primary: Enrollment Into Weekly Testing by Each Participant - Special School District — 0.47; 0.49 % of participants enrolled per week — p=>0.99
HIV Infections · Drug Use · Opioid Use
Primary: Number and Percentage of Participants With Documented Current Use of MOUD at Week 26 by Site — 30; 22; 6; 4 Participants — p=0.213
Tissue Reaction · Elevated Blood Ion Levels
Primary: Asymptomatic vs Symptomatic Metal-on-Metal and Metal-on-Poly Patients (Via a Proportion) With a Soft Tissue Mass — 1; 5; 22; 23 Participants
Anesthesia, Local · Photodamaged Skin · Topical and Infiltration Anesthetic Toxicity
Primary: Self-reported Pain After Laser Treatment — 4.5; 5.0 score on a scale — p=0.102
PTSD
Primary: PTSD Checklist for DSM-5 (PCL-5) — 30.8 Scores on a Scale
Coronary Syndrome
Primary: Bleeding Time Difference — 0; 75; -15 s
Spinal Cord Injuries · Tetraplegia · Quadriplegia
Primary: Ability to Form Appropriate Grasp Patterns — 78.75 percentage of correct grasps formed
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Follicular Lymphoma
Primary: Part A: The Recommended Dose for Expansion (RDFE) of BGB-10188 Monotherapy in Hematologic Malignancies — NA mg
Hyper-low-density Lipoprotein (LDL) Cholesterolemia
Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 109 Participants
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis
Primary: Percentage of Participants With Psoriasis Area Severity Index 90 (PASI90) Response at Week 16 — 3.0; 94.0 percentage of participants — p=<0.001
Solid Neoplasms With NTRK Fusions
Primary: Duration of Response (DoR) — 24.5 months
Colorectal Cancer
Primary: TRPM7 Expression Level in Colorectal Mucosa by Mg Treatment Compared With Placebo — 0.03; 0.08; -0.09; -0.11 log (arbitrary units) — p=>0.05
Opioid Use Disorder · HIV Infections · Chlamydia
Primary: Evaluate Uptake of Pre-exposure Prophylaxis (PrEP) — 10 Participants
Mild Cognitive Impairment
Primary: Mean Change in ADL Score From Baseline to Week 10 — 0.00; -0.29 score on a scale
Oral Cancer · Smoking · DNA Damage
Primary: HPB-releasing Adducts (Buccal Cells) — 0.67 picogram HPB/microgram guanine — p=0.368